Actualización sobre la entrega oral
Energía Essar
69.50p
16:35 09/06/14
18 de abril de 2024
N4 Farmacéutica
("N4 Pharma" o la "Compañía")
Actualización sobre la entrega oral
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work.
The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads.
Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control.
Nigel Theobald, Director Ejecutivo de la Compañía, comentó:
"This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples.
"We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them."
Para más información, por favor contacte:
N4 Farmacéutica Nigel Theobald, director ejecutivo Lucas Cairns, Director Ejecutivo
Interactúe con nosotros directamente en N4 Pharma Investor Hub
Para saber más, visite |
A través del Centro de inversores N4 Pharma
Regístrese en inversores.n4pharma.com
https://investors.n4pharma.com/link/oPBR0P |
SP Ángel Corporativo Finanzas LLP Asesor designado y conjunto Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Finanzas corporativas) Vadim Alexandre/Abigail Wayne/Rob Rees (corredores corporativos) | Tel: + 44 (0) 20 3470 0470 |
Turner Papa Inversiones (TPI) Limited Conjunto Broker Andy Thacker papa james | Tel: + 44 (0) 20 3657 0050 |
Acerca de N4 Pharma
N4 Pharma es una empresa farmacéutica especializada que desarrolla un novedoso sistema de administración para oncología, terapia génica y vacunas utilizando su exclusivo sistema de administración de nanopartículas de sílice llamado Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
Para más información sobre la empresa visite www.n4pharma.com o regístrate en inversores.n4pharma.com.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.